Current status and future perspectives of FGF21 analogues in clinical trials
Trends in Endocrinology & Metabolism · 2024-05 · 35 (5) · 371-384
DOI: 10.1016/j.tem.2024.02.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2024-05. Verfasst von Zara Siu Wa Chui und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, China; Department of Medicine, The University of H…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Obesity. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Research Grants Council, University Grants Committee.
Abstract (Originalsprache)
Recent advances in fibroblast growth factor 21 (FGF21) biology and pharmacology have led to the development of several long-acting FGF21 analogues and antibody-based mimetics now in various phases of clinical trials for the treatment of obesity-related metabolic comorbidities. The efficacy of these FGF21 analogues/mimetics on glycaemic control and weight loss is rather mild and inconsistent; nevertheless, several promising therapeutic benefits have been reproducibly observed in most clinical studies, including amelioration of dyslipidaemia (particularly hypertriglyceridaemia) and hepatic steatosis, reduction of biomarkers of liver fibrosis and injury, and resolution of metabolic dysfunction-associated steatohepatitis (MASH). Evidence is emerging that combination therapy with FGF21 analogues and other hormones (such as glucagon-like peptide 1; GLP-1) can synergise their pharmacological benefits, thus maximising the therapeutic efficacy for obesity and its comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, China; Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China; School of Biomedical Sciences, The Un…
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, China; Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China.
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, China; Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China; Department of Pharmacology and Pharma…
Förderung
- National Natural Science Foundation of China
- Research Grants Council, University Grants Committee
Zitieren
APA
Chui, Z. S. W., Shen, Q., & Xu, A. (2024). Current status and future perspectives of FGF21 analogues in clinical trials. Trends in Endocrinology & Metabolism, 35(5), 371-384. https://doi.org/10.1016/j.tem.2024.02.001
Vancouver
Chui ZSW, Shen Q, Xu A. Current status and future perspectives of FGF21 analogues in clinical trials. Trends in Endocrinology & Metabolism. 2024;35(5):371-384. doi:10.1016/j.tem.2024.02.001
BibTeX
@article{Chui2024,
author = {Chui, Zara Siu Wa and Shen, Qing and Xu, Aimin},
title = {Current status and future perspectives of FGF21 analogues in clinical trials},
journal = {Trends in Endocrinology & Metabolism},
year = {2024},
volume = {35},
number = {5},
pages = {371--384},
doi = {10.1016/j.tem.2024.02.001}
}
EUVIMED